You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 292 No. 3, July 21, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Similar articles in JAMA
 Topic Collections
 •Immunization
 •Prognosis/ Outcomes
 •Alert me on articles by topic

MMR Vaccination and Febrile Seizures

Evaluation of Susceptible Subgroups and Long-term Prognosis

Mogens Vestergaard, MD, PhD; Anders Hviid, MSci; Kreesten Meldgaard Madsen, MD, PhD; Jan Wohlfahrt, MSci; Poul Thorsen, MD, PhD; Diana Schendel, PhD; Mads Melbye, MD, DMSci; Jørn Olsen, MD, PhD

JAMA. 2004;292:351-357.

Context  The rate of febrile seizures increases following measles, mumps, and rubella (MMR) vaccination but it is unknown whether the rate varies according to personal or family history of seizures, perinatal factors, or socioeconomic status. Furthermore, little is known about the long-term outcome of febrile seizures following vaccination.

Objectives  To estimate incidence rate ratios (RRs) and risk differences of febrile seizures following MMR vaccination within subgroups of children and to evaluate the clinical outcome of febrile seizures following vaccination.

Design, Setting, and Participants  A population-based cohort study of all children born in Denmark between January 1, 1991, and December 31, 1998, who were alive at 3 months; 537 171 children were followed up until December 31, 1999, by using data from the Danish Civil Registration System and 4 other national registries.

Main Outcome Measures  Incidence of first febrile seizure, recurrent febrile seizures, and subsequent epilepsy.

Results  A total of 439 251 children (82%) received MMR vaccination and 17 986 children developed febrile seizures at least once; 973 of these febrile seizures occurred within 2 weeks of MMR vaccination. The RR of febrile seizures increased during the 2 weeks following MMR vaccination (2.75; 95% confidence interval [CI], 2.55-2.97), and thereafter was close to the observed RR for nonvaccinated children. The RR did not vary significantly in the subgroups of children that had been defined by their family history of seizures, perinatal factors, or socioeconomic status. At 15 to 17 months, the risk difference of febrile seizures within 2 weeks following MMR vaccination was 1.56 per 1000 children overall (95% CI, 1.44-1.68), 3.97 per 1000 (95% CI, 2.90-5.40) for siblings of children with a history of febrile seizures, and 19.47 per 1000 (95% CI, 16.05-23.55) for children with a personal history of febrile seizures. Children with febrile seizures following MMR vaccinations had a slightly increased rate of recurrent febrile seizures (RR, 1.19; 95% CI, 1.01-1.41) but no increased rate of epilepsy (RR, 0.70; 95% CI, 0.33-1.50) compared with children who were nonvaccinated at the time of their first febrile seizure.

Conclusions  MMR vaccination was associated with a transient increased rate of febrile seizures but the risk difference was small even in high-risk children. The long-term rate of epilepsy was not increased in children who had febrile seizures following vaccination compared with children who had febrile seizures of a different etiology.


Author Affiliations: The Danish Epidemiology Science Centre, Department of Epidemiology and Social Medicine, Aarhus University, Aarhus (Drs Vestergaard, Madsen, and Olsen), The Danish Epidemiology Science Centre, Department of Epidemiology Research, Statens Serum Institut, Copenhagen (Dr Melbye and Mr Hviid and Ms Wohlfahrt), and North Atlantic Neuro-Epidemiology Alliances, Department of Epidemiology and Social Medicine, Aarhus (Drs Thorsen and Schendel), Denmark; and National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Ga (Dr Schendel).


RELATED LETTER

MMR Vaccination and Febrile Seizures
Eelko Hak and Marc J. M. Bonten
JAMA. 2004;292(17):2083.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Risk of Serious Neurologic Disease After Immunization of Young Children in Britain and Ireland
Ward et al.
Pediatrics 2007;120:314-321.
ABSTRACT | FULL TEXT  

The Long-Term Risk of Epilepsy after Febrile Seizures in Susceptible Subgroups
Vestergaard et al.
Am J Epidemiol 2007;165:911-918.
ABSTRACT | FULL TEXT  

Evaluation of Potentially Common Adverse Events Associated With the First and Second Doses of Measles-Mumps-Rubella Vaccine
LeBaron et al.
Pediatrics 2006;118:1422-1430.
ABSTRACT | FULL TEXT  

Journal Watch
Arch. Dis. Child. 2005;90:106-107.
FULL TEXT  

Journal Watch
Arch. Dis. Child. 2004;89:1175-1176.
FULL TEXT  

MMR Vaccination and Febrile Seizures
Hak and Bonten
JAMA 2004;292:2083-2083.
FULL TEXT  

MMR Vaccine Does Not Increase Long-Term Risk for Epilepsy
JWatch Emergency Med. 2004;2004:5-5.
FULL TEXT  

Febrile Seizures After MMR Do Not Increase Risk for Epilepsy
JWatch Pediatrics 2004;2004:4-4.
FULL TEXT  

MMR and Febrile Seizures
JWatch General 2004;2004:3-3.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.